Pharvaris Share Price

Pharvaris Share Price

NASDAQ: PHVS | Healthcare
$31.51
-$0.80 (-2.48%) Last updated on 19 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Pharvaris Stock Performance

Open
$32.24
Prev. Close
$32.31
Circuit Range
N/A
Day Range
$31.22 - $32.45
Year Range
$23.25 - $43.03
Volume
27,636
Average Traded
$31.64

Pharvaris Share Price Today

As of 19 November 2026, Pharvaris N.V.'s share price is $31.51. The stock opened at $32.24, compared to its previous close of $32.31. During today's trading session, Pharvaris N.V.'s share price traded between $31.22 and $32.45, with an average price of $31.84. Over the past 52 weeks, the stock has recorded a high of $43.03 and a low of $23.25. In terms of performance, Pharvaris N.V.'s share price has risen by 4.48% over the last six months and is up 11.42% on a year-on-year basis.

Pharvaris Share Price Chart

Line chart of the Pharvaris price trend over the selected period. The price fell overall, ranging from 31.22 to 32.45, ending at 31.51.
$31.22$32.45
L
Show Current Price
H

Pharvaris Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$0.00
Return On Equity (TTM)
N/A
Profit Margin
N/A
Debt to Equity
N/A
Quarterly Earnings Growth YoY
N/A

Pharvaris Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$81.86-$111.58-$139.51-$206.62
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-36.31%-25.03%-48.10%

Pharvaris Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets3.342.511.40.95
Current Assets350.35300.68439.34178.97
Total Assets353.69303.19440.74179.92
Non Current Liabilities0.680.660.050.27
Current Liabilities34.7323.9116.1419.55
Total Liabilities35.4124.5716.1919.82
Shareholders' Equity318.28278.62424.55160.11

Pharvaris Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-160.82-125.0-102.86-72.04
Investing-0.19-0.56-0.1-0.13
Financing188.442.79359.719.28

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Pharvaris Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$34.06
$31.51
-5.91%
Oct 2026
$31.57
$33.49
+5.36%
Sep 2026
$34.02
$31.79
-14.16%
Aug 2026
$32.34
$37.03
+13.59%
Jul 2026
$34.20
$32.60
-5.51%
Jun 2026
$29.47
$34.50
+14.39%
May 2026
$30.69
$30.16
-2.82%
Apr 2026
$27.78
$31.04
+9.92%
Mar 2026
$28.36
$28.23
-0.49%
Feb 2026
$27.89
$28.38
+4.84%
Jan 2026
$27.70
$27.07
-2.45%
Dec 2025
$28.39
$27.75
-1.89%

Pharvaris Share Price FAQs